Related references
Note: Only part of the references are listed.Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice
Shinnosuke Tsuji et al.
NATURE BIOTECHNOLOGY (2022)
Gene Therapy in Combination with Nitrogen Scavenger Pretreatment Corrects Biochemical and Behavioral Abnormalities of Infant Citrullinemia Type 1 Mice
Andrea Bazo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice
Michela Lisjak et al.
FRONTIERS IN GENOME EDITING (2022)
Outcome of Liver Transplantation for Neonatal-onset Citrullinemia Type I
Yuan Liu et al.
TRANSPLANTATION (2021)
DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Chaoyou Xue et al.
TRENDS IN GENETICS (2021)
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
Lindsey A. George et al.
MOLECULAR THERAPY (2020)
Genome editing technologies to treat rare liver diseases
Marta Trevisan et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
K. John Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision
Johannes Haberle et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
Liver transplantation for neonatal-onset citrullinemia
Roshni Vara et al.
PEDIATRIC TRANSPLANTATION (2018)
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration
Amine Meliani et al.
NATURE COMMUNICATIONS (2018)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape
Federico Mingozzi et al.
ANNUAL REVIEW OF VIROLOGY, VOL 4 (2017)
Mediation of cellular osteogenic differentiation through daily stimulation time based on polypyrrole planar electrodes
Zongguang Liu et al.
SCIENTIFIC REPORTS (2017)
Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model
Fabiola Porro et al.
EMBO MOLECULAR MEDICINE (2017)
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang Yang et al.
NATURE BIOTECHNOLOGY (2016)
A universal system to select gene-modified hepatocytes in vivo
Sean Nygaard et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome
Giuseppe Ronzitti et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system
Sharon C. Cunningham et al.
HEPATOLOGY (2015)
Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update
Ljubica Caldovic et al.
JOURNAL OF GENETICS AND GENOMICS (2015)
Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency
Jin-Ho Choi et al.
JOURNAL OF HUMAN GENETICS (2015)
Promoter less gene targeting without nucleases ameliorates haemophilia B in mice
A. Barzel et al.
NATURE (2015)
Genome Engineering with Targetable Nucleases
Dana Carroll
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 83 (2014)
Molecular genetics of citrullinemia types I and II
Hye In Woo et al.
CLINICA CHIMICA ACTA (2014)
Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Crigler-Najjar Syndrome
Giulia Bortolussi et al.
HUMAN GENE THERAPY (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The new frontier of genome engineering with CRISPR-Cas9
Jennifer A. Doudna et al.
SCIENCE (2014)
Liver-directed adeno-associated virus serotype 8 gene transfer rescues a lethal murine model of citrullinemia type 1
R. J. Chandler et al.
GENE THERAPY (2013)
Adeno-associated Virus-mediated Rescue of Neonatal Lethality in Argininosuccinate Synthetase-deficient Mice
Cindy Y. Kok et al.
MOLECULAR THERAPY (2013)
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
Yanfang Fu et al.
NATURE BIOTECHNOLOGY (2013)
Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 Vector
Lili Wang et al.
HUMAN GENE THERAPY (2012)
Double-Strand Break End Resection and Repair Pathway Choice
Lorraine S. Symington et al.
ANNUAL REVIEW OF GENETICS, VOL 45 (2011)
State-of-the-art gene-based therapies: the road ahead
Mark A. Kay
NATURE REVIEWS GENETICS (2011)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Two Hypomorphic Alleles of Mouse Ass1 as a New Animal Model of Citrullinemia Type I and Other Hyperammonemic Syndromes
Carlos J. Perez et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
β-adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the α- and γ-adducin subunits
F. Porro et al.
GENES BRAIN AND BEHAVIOR (2010)
Gene delivery to the juvenile mouse liver using AAV2/8 vectors
Sharon C. Cunningham et al.
MOLECULAR THERAPY (2008)
Efficient transposition of the piggyBac resource (PB) transposon in mammalian cells and mice
S Ding et al.
CELL (2005)
JCat:: a novel tool to adapt codon usage of a target gene to its potential expression host
A Grote et al.
NUCLEIC ACIDS RESEARCH (2005)
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
JD Mount et al.
BLOOD (2002)
Medical progress - The hemophilias - From royal genes to gene therapy
PM Mannucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
LL Wang et al.
MOLECULAR THERAPY (2000)
Share Paper
